Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALVAC-HIV + AIDSVAX B/E in Healthy Adults
NCT02109354Phase 1Completed
- Sponsor
- HIV Vaccine Trials Network
- Start
- Jun 2013
- Primary completion
- Feb 2015
- Modality
- Prophylactic Vaccines, Viral Vectors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ALVAC-HIV and AIDSVAX B/E in human immunodeficiency virus infection (HIV) (3 arms), sponsored by HIV Vaccine Trials Network. Primary endpoints: Frequency of local and systemic reactogenicity signs and symptoms at 13.5 months, HIV-specific total IgG and IgA binding antibody responses and 8 more. Started Jun 2013; status: completed.
02
Drugs
ALVAC-HIVAIDSVAX B/E
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02109354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02109354.